Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P880086/S346

Assurity, Assurity+, Endurity, Accent family of Pacemakers

ABBOTT MEDICAL · Decision date Apr 24, 2026

FDA DECISIONP880086/S346

What did the FDA approve?

FDA records P880086/S346 as a supplement to PMA P880086, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 24, 2026.

FDA approval order statement

the Merlin PCS Programmer Software Model 3330 version 28.8.1
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Apr 24, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P880086/S346
Regulatory pathway
PMA supplement
Product code
DXY
Decision code
APPR
Decision date
Apr 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: implantable pacemaker Pulse-generator.

Product code
DXY
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P880086/S346 received

    Application receipt date recorded by FDA.

  2. P880086/S346 · FDA decision

    Real-Time Process

  3. P880086/S345 · Related supplement

    Assurity, Assurity+, Endurity, Accent family of Pacemakers

Timeline entries are records held by MedtechLedger for P880086. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P880086

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementJul 21, 2026FDA

Explore the linked device profile

Other records with product code DXY

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91335

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records